Pharmaceutical

“No magic wand” for Novo Nordisk, as CagriSema pen supply rumours swirl

Novo Nordisk and Ypsomed’s 2023 deal is rumoured to include an autoinjector supply for potential Wegovy successor CagriSema.

Nov 23, 2024 - 06:00
“No magic wand” for Novo Nordisk, as CagriSema pen supply rumours swirl
Novo Nordisk and Ypsomed’s 2023 deal is rumoured to include an autoinjector supply for potential Wegovy successor CagriSema.
Read the original article

Tags:

Previous Article

J&J eyes FDA approval for injection-based Tremfya in ulcerative colitis

Next Article

Health Canada issues NOC to J&J’s CARVYKTI for multiple myeloma

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Michigan bill that would pare back pharma liability shield law moves closer to enactment

STAT+: Michigan bill that would pare back pharma liabil...

Nov 13, 2023

STAT+: AstraZeneca bets that gene therapy’s workhorse will still deliver the goods

STAT+: AstraZeneca bets that gene therapy’s workhorse w...

Sep 2, 2023

Intercept suffers setback with negative AdCom decision for NASH therapy

Intercept suffers setback with negative AdCom decision ...

May 22, 2023